Related Experiment Video

Updated: May 17, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance

H Ray-David1, Y Romeo, G Lavoie

  • 1Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, Quebec, Canada.

Oncogene
|October 31, 2012
PubMed

Insights

RSK, a protein kinase, promotes melanoma chemoresistance by inhibiting Chk1, a key DNA damage response protein. RSK inhibitors may overcome this resistance, improving melanoma treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Malignant melanoma incidence is rising globally, with limited effective therapies for metastatic disease.
  • Melanoma exhibits high resistance to DNA-damaging chemotherapeutics, necessitating research into underlying molecular mechanisms.
  • The Ras/mitogen-activated protein kinase (MAPK) pathway, often deregulated by NRAS/BRAF mutations, is implicated in melanoma development and chemoresistance.

Purpose of the Study:

  • To investigate the role of MAPK-activated protein kinase RSK (p90 ribosomal S6 kinase) in melanoma chemoresistance.
  • To elucidate the molecular mechanism by which RSK influences the DNA damage response and chemosensitivity in melanoma cells.

Main Methods:

  • In vitro and in vivo biochemical assays to assess RSK's phosphorylation of checkpoint kinase 1 (Chk1).
  • Analysis of RSK's role in regulating Chk1 activity and the G2 DNA damage checkpoint.
  • Evaluation of RSK inhibitors' effects on melanoma cell chemosensitivity to DNA-damaging agents.

Main Results:

  • RSK was identified as a key mediator of melanoma chemoresistance, phosphorylating Chk1 at an inhibitory site (Ser280).
  • RSK constitutively phosphorylates Chk1 in melanoma cells, downstream of the Ras/MAPK pathway.
  • RSK inhibition enhanced Chk1 activity in response to DNA damage and promoted G2 DNA damage checkpoint silencing in a Chk1-dependent manner.
  • RSK inhibitors sensitized melanoma cells to DNA-damaging chemotherapeutics.

Conclusions:

  • RSK plays a critical role in melanoma chemoresistance by modulating the DNA damage response through Chk1.
  • Targeting RSK represents a potential therapeutic strategy to enhance chemosensitivity and overcome treatment resistance in melanoma.
  • This study reveals a novel link between the Ras/MAPK pathway and DNA damage response modulation in melanoma.

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Visualization of DNA Repair Proteins Interaction by Immunofluorescence07:55

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Published on: June 26, 2020

Related Concept Videos

DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...